4.8 Article

Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer

Journal

NATURE COMMUNICATIONS
Volume 12, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41467-020-20820-x

Keywords

-

Funding

  1. Swiss National Science Foundation [PP00P3_150645, PP00P3_179072]
  2. Swiss Cancer League
  3. Lega Ticinese contro il cancro
  4. Fidinam Foundation
  5. National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium [NIH/NCI U24-CA210986, NIH/NCI U01 CA214125]
  6. Swiss National Science Foundation (SNF) [PP00P3_150645, PP00P3_179072] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Mutually exclusive prostate cancer driver alterations involving ERG transcription factor and ubiquitin ligase adaptor SPOP have synthetic sick effects, regulating the response to therapeutic interventions in the AR pathway. This dichotomy highlights a distinct class of antagonistic cancer drivers and provides a blueprint for therapeutic exploitation.
Driver genes with a mutually exclusive mutation pattern across tumor genomes are thought to have overlapping roles in tumorigenesis. In contrast, we show here that mutually exclusive prostate cancer driver alterations involving the ERG transcription factor and the ubiquitin ligase adaptor SPOP are synthetic sick. At the molecular level, the incompatible cancer pathways are driven by opposing functions in SPOP. ERG upregulates wild type SPOP to dampen androgen receptor (AR) signaling and sustain ERG activity through degradation of the bromodomain histone reader ZMYND11. Conversely, SPOP-mutant tumors stabilize ZMYND11 to repress ERG-function and enable oncogenic androgen receptor signaling. This dichotomy regulates the response to therapeutic interventions in the AR pathway. While mutant SPOP renders tumor cells susceptible to androgen deprivation therapies, ERG promotes sensitivity to high-dose androgen therapy and pharmacological inhibition of wild type SPOP. More generally, these results define a distinct class of antagonistic cancer drivers and a blueprint toward their therapeutic exploitation. Gene fusions involving the ERG transcription factor and point mutations in the ubiquitin ligase adaptor SPOP are two truncal mutations that are mutually exclusively present in prostate cancer. Here, the authors show that mutations in SPOP render prostate tumor cells sensitive to antiandrogen therapy and that the presence of ERG promotes sensitivity to high dose of androgen and SPOP inhibition.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available